Lenacapavir (Sunlenca) vs VH4004280 (VH-280)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Lenacapavir (Sunlenca)
Marketed by Gilead Sciences
NCT04143594 · Phase 2 · completed
The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.
Next expected readout: March 2027 · NCT06749054 (registry estimate)
Reported efficacy
Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants (met)
Result source: NCT04150068
VH4004280 (VH-280)
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.
Reported efficacy
Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11); Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) (unclear)
Result source: NCT06039579
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lenacapavir (Sunlenca) | VH4004280 (VH-280) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 90.4% vs 92%vs B/F/TAFNCT0414359411 other results
| —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06532656 | —Not reported |
| CD4 count, change (week 48) | 275 vs 248vs B/F/TAFNCT0414359411 other results
| —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Lenacapavir (Sunlenca)
- 90.4% vs 92%vs B/F/TAFNCT04143594
11 other results
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
- VH4004280 (VH-280)
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Lenacapavir (Sunlenca)
- —Trial running · NCT06532656
- VH4004280 (VH-280)
- —Not reported
CD4 count, change (week 48)
- Lenacapavir (Sunlenca)
- 275 vs 248vs B/F/TAFNCT04143594
11 other results
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- VH4004280 (VH-280)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lenacapavir (Sunlenca): 4 of 4 rows · VH4004280 (VH-280): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lenacapavir (Sunlenca) | VH4004280 (VH-280) |
|---|---|---|
| Dropout rate | 21.2%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 16.7%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 14.3%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | 0%Dose Level 1b NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%900 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%350 mg NCT05163522 · Phase 1 · monotherapy 0%250 mg + Midazolam NCT05163522 · Phase 1 · combination 0%150 mg NCT05163522 · Phase 1 · monotherapy 0%100 mg NCT05163522 · Phase 1 · monotherapy 14.3%50 mg NCT05163522 · Phase 1 · monotherapy 0%10 mg NCT05163522 · Phase 1 · monotherapy |
| Discontinued due to AEs | 1.9%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination —750 mg NCT03739866 · Phase 1 · registry result, not featured evidence —450 mg NCT03739866 · Phase 1 · registry result, not featured evidence —150 mg NCT03739866 · Phase 1 · registry result, not featured evidence —50 mg NCT03739866 · Phase 1 · registry result, not featured evidence —20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | —Dose Level 1b NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —900 mg NCT05163522 · Phase 1 · monotherapy —450 mg NCT05163522 · Phase 1 · monotherapy —450 mg NCT05163522 · Phase 1 · monotherapy —350 mg NCT05163522 · Phase 1 · monotherapy —250 mg + Midazolam NCT05163522 · Phase 1 · combination —150 mg NCT05163522 · Phase 1 · monotherapy —100 mg NCT05163522 · Phase 1 · monotherapy —50 mg NCT05163522 · Phase 1 · monotherapy —10 mg NCT05163522 · Phase 1 · monotherapy |
| Serious AEs | 7.7%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 0%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | —Dose Level 1b NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results0%Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%900 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%350 mg NCT05163522 · Phase 1 · monotherapy 0%250 mg + Midazolam NCT05163522 · Phase 1 · combination 0%150 mg NCT05163522 · Phase 1 · monotherapy 0%100 mg NCT05163522 · Phase 1 · monotherapy 0%50 mg NCT05163522 · Phase 1 · monotherapy 0%10 mg NCT05163522 · Phase 1 · monotherapy |
| Most frequent reported AEs | a injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · combination show 7 more resultsinjection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · combination 750 mg injection site pain 80% (placebo 30%) injection site erythema 40% (placebo 10%) injection site nodule 40% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 450 mg injection site pain 66.7% (placebo 30%) upper respiratory tract infection 66.7% (placebo 0%) injection site erythema 33.3% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 150 mg injection site erythema 66.7% (placebo 10%) injection site pain 66.7% (placebo 30%) injection site induration 50% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 50 mg injection site pain 66.7% (placebo 30%) syphilis 33.3% (placebo 0%) acne 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 20 mg headache 33.3% (placebo 20%) anogenital dysplasia 16.7% (placebo 0%) conjunctivitis allergic 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence | Dose Level 1b transaminases increased 16.7% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) arthralgia 0% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 show 14 more resultsDose Level 1 headache 16.7% (placebo 0%) periodontitis 16.7% (placebo 0%) rhinitis allergic 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Dose Level 2 blood creatinine increased 33.3% (placebo 0%) pyrexia 16.7% (placebo 0%) thrombocytopenia 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Dose Level 2 blood creatinine increased 33.3% (placebo 0%) hypertriglyceridaemia 33.3% (placebo 0%) cough 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose cough 16.7% (placebo 0%) pharyngitis 16.7% (placebo 0%) rhinitis 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose alanine aminotransferase increased 16.7% (placebo 0%) dengue fever 16.7% (placebo 0%) urticaria 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 900 mg headache 16.7% (placebo 0%) abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) NCT05163522 · Phase 1 · monotherapy 450 mg abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) amylase increased 0% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 450 mg alanine aminotransferase increased 16.7% (placebo 10%) amylase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 10%) NCT05163522 · Phase 1 · monotherapy 350 mg alanine aminotransferase increased 16.7% (placebo 10%) aspartate aminotransferase increased 16.7% (placebo 10%) bile acids increased 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 250 mg + Midazolam fatigue 62.5% (placebo 0%) blood creatine phosphokinase increased 25% (placebo 0%) low density lipoprotein increased 25% (placebo 0%) NCT05163522 · Phase 1 · combination 150 mg abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) amylase increased 0% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 100 mg dyslipidaemia 33.3% (placebo 0%) bile acids increased 16.7% (placebo 0%) blood bilirubin increased 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 50 mg abdominal discomfort 28.6% (placebo 0%) diarrhoea 28.6% (placebo 0%) body temperature increased 14.3% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 10 mg chapped lips 16.7% (placebo 0%) dermatitis contact 16.7% (placebo 10%) dry mouth 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lenacapavir (Sunlenca)
show 16 more results
show 16 more results
show 11 more results
VH4004280 (VH-280)
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenacapavir (Sunlenca)'s landscape · VH4004280 (VH-280)'s landscape